New studies, financing rounds & more — 5 GI company key notes

Here are five updates on GI companies from the past week:

Advertisement

RedHill Biopharma reported positive study results concerning its irritable bowel syndrome with diarrhea drug Bekinda, yet investors sent the drugmaker’s stock tumbling.

A study, published in Digestive Diseases and Sciences, analyzed the efficacy of Medial EarlySign’s ColonFlag.

Valeant Pharmaceuticals sold its iNova Pharmaceuticals business to a company jointly owned by Pacific Equity Partners and The Carlyle Group for $930 million.

Landos Biopharma completed a series A financing round raising $10 million.

The FDA approved Bracco Diagnostics’ Tagitol V oral suspension for adult patients undergoing virtual colonoscopy.

More articles on gastroenterology: 
GI leader to know: Dr. Steven Desautels of Granite Peaks Gastroenterology
Stock market week-in-review for 5 large GI companies — Sept. 25-29
Drug designations, new devices & more — 15 GI company key notes for September

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.